ERBB2 and breast carcinoma: Restricted by the complex operating procedures and instability of output results from current clinical detection methods, the reference value of marker proteins detection results, such as human epidermal growth factor receptor 2 (HER2) in the early screening of breast cancer has been reduced (Lamtha et al., 2021; Tang et al., 2021).